


In the Claims

1-20 (canceled).

21 (new). A compound selected from the group consisting of:
a compound of formula I



wherein R_1 and R_2 are independently hydrogen, a straight chained C_{1-6} alkyl group optionally substituted with a phenyl group, or a branched C_{1-6} alkyl group optionally substituted with a phenyl group, or

R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein the heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl, nitro group, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally an N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

X is halogen or $-NR_4R_5$, wherein R_4 and R_5 are independently hydrogen, a straight chained C_{1-6} alkyl group or a branched C_{1-6} alkyl group,

Y is a hydrogen, hydroxy group, halogen, or C_{1-22} acyloxy group, wherein if R_4 and R_5 are both hydrogen, then Y is other than a hydroxy group,

with the proviso that

a) if Y is hydrogen and/or X is an $-NR_4R_5$ or if X is $-NR_4R_5$ group,

R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein the heterocyclic ring is substituted with one or more hydroxy, oxy, or benzyl groups, and/or


A is a nitrogen containing heteroaromatic ring, wherein said ring has an N-oxide structure on the nitrogen heteroatom, or

b) if X is halogen and Y is hydroxy or acyloxy,

R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups,

or a stereoisomer or salt thereof;

a compound of formula II



wherein R_1 and R_2 are independently hydrogen, a straight chained C_{1-6} alkyl group optionally substituted with a phenyl group, a branched C_{1-6} alkyl group optionally substituted with a phenyl group, or

R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups,

A is a phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected

from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally an N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

X is oxygen;

R₃ is selected from the group consisting of hydrogen, straight chained C₁₋₆ alkyl group, and branched chained C₁₋₆ alkyl group;

Y is selected from the group consisting of hydrogen, hydroxy, halogen, and C₁₋₂₂ acyloxy group,


with the proviso that if Y is other than halogen,

R₁ and R₂ together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups and/or

A is a nitrogen containing heteroaromatic ring, which has N-oxide structure on the nitrogen heteroatom;

or a stereoisomer or salt thereof; and

a compound of formula III



wherein R₁ and R₂ are independently hydrogen, straight chained C₁₋₆ alkyl group optionally substituted with a phenyl group, branched C₁₋₆ alkyl group optionally substituted with a phenyl group, or

R₁ and R₂ together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more C₁₋₄ alkyl, C₁₋₄ haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally an N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

with the proviso that

if R₁ and R₂ independently represent a hydrogen atom, a straight chained C₁₋₆ alkyl group optionally substituted with a phenyl group, a branched C₁₋₆ alkyl group optionally substituted with a phenyl group, or together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, then A is a heteroaromatic ring containing oxygen or sulfur heteroatom or an N-containing heteroaromatic ring having an N-oxide structure on the nitrogen heteroatom and

if A is a phenyl group optionally substituted with one or more C₁₋₄ alkyl, C₁₋₄ haloalkyl or nitro groups or halogen, or is a 5-6 membered N-containing heteroaromatic ring, then R₁ and R₂ together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo, or benzyl groups;

or a stereoisomer or salt thereof.

22 (new). The compound according to claim 21, wherein the compound is N-[3-(1-piperidinyl)propoxy]-pyridin-1-oxide-3-carboxamidine or a salt thereof.

23 (new). The compound according to claim 21, wherein the compound is N-[3-(1-piperidinyl)propoxy]-pyridin-1-oxide-3-carboxamidine or salts.

24 (new). The compound according to claim 21, wherein the compound is N-[2-hydroxy-3-(1-piperidinyl)propoxy]-N'-n-butyl-pyridin-1-oxide-4-carboxamide, or a stereoisomer and/or salt thereof.

25 (new). The compound according to claim 21, wherein the compound is N-[3-(1-oxido-1-piperidinyl)propoxy]-3-nitro-benzimidoyl-chloride, or a hydrate and/or salt thereof.

26 (new). The compound according to claim 21, wherein the compound is 2-chloro-N-[3-(4-oxido-4-morpholinyl)propoxy]-benzimidoyl chloride or a salt thereof.

27 (new). The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

28 (new). The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(4-benzyl-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

29 (new). The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(4-benzyl-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

30 (new). The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

31 (new). The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-oxido-1-piperidinyl)methyl]-3-(oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

32 (new). The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(4-hydroxy-1-piperidiny)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

33 (new). The compound according to claim 21, wherein the compound is N-[2-chloro-3-(1-piperidiny)propoxy]-3-benzimidoyl-chloride hydrochloride, or a stereoisomer and/or salt thereof.

34 (new). The compound according to claim 21, wherein the compound is N-[2-hydroxy-3-(1-piperidiny)propoxy]-pyridin-1-oxide-3-carboxamidine, or a stereoisomer and/or salt thereof.

35 (new). A pharmaceutical composition comprising a compound of formulae I, II, or III as defined in claim 22.

36 (new). A method for the treatment or prevention of vascular disease or diseases related to vascular disorders comprising administering an effective amount of a compound to a patient, wherein the compound is a compound of formulae I, II, or III as defined in claim 22.